The startup provides a minimally invasive tumor ablation service utilizing Irreversible Electroporation (IRE) technology, which eliminates the need for muscle relaxants and reduces anesthesia requirements. This approach addresses challenges associated with traditional IRE methods, such as limited range and difficulties in needle placement, while ensuring no impact on patients' heart rates.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional Irreversible Electroporation (IRE) tumor ablation methods often require muscle relaxants and general anesthesia, posing risks and increasing costs. These methods can also be limited by range constraints and challenges in precise needle placement, potentially affecting treatment efficacy.
Solution
This startup offers a minimally invasive tumor ablation service using Irreversible Electroporation (IRE) technology designed to overcome the limitations of conventional IRE. Their approach eliminates the need for muscle relaxants and reduces anesthesia requirements, minimizing patient risk and recovery time. The technology also addresses range limitations and needle placement difficulties, potentially improving the precision and effectiveness of tumor ablation without impacting the patient's heart rate.
Target Audience
The primary target audience includes hospitals, oncology centers, and surgeons specializing in tumor ablation procedures.
Features
- Minimally invasive tumor ablation using Irreversible Electroporation (IRE)
- Elimination of muscle relaxants during the procedure
- Reduced anesthesia requirements
- Enhanced precision in needle placement
- No impact on patient heart rate